Leading Chinese maker of recombinant human growth hormone (rhGH) and other biologic drugs.
Leading Chinese maker of recombinant human growth hormone (rhGH) and other biologic drugs.
In one line: A Chinese Genentech/Novo Nordisk for growth hormone.
Moat: narrow (regulatory licence, brand, scale). Long-standing leadership and manufacturing scale in China's growth-hormone market.
Headquarters: Hefei, Anhui, China · Employees: 2,505
Size Anhui Anke Biotechnology (Group) (300009.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.88B, the 1229th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥7.56 on 18 Nov 2026.
Performance Over six months the shares fell 12.5%, against -7.3% for the median peer and -20.0% for the China market (cap-weighted) — 9th lowest of 21 in its peer set.
Growth Revenue fell 9.4% over the last twelve months (peer median +11.8%); the operating margin is 30.0% (peer median 13.3%).
Valuation It trades at 18.1× forward earnings against a peer median of 18.4× (10th cheapest of 19).
Price implies For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is -1 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 10.0 points above its cost of capital (9.1% WACC).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.34B | CN¥2.63B | CN¥2.52B | CN¥2.85B | CN¥2.32B |
| Revenue growth | — | +4% | -11% | +23% | — |
| Gross profit | CN¥1.82B | CN¥1.95B | CN¥1.91B | CN¥2.19B | CN¥1.77B |
| EBITDA | n/a | CN¥912M | CN¥863M | CN¥1.01B | CN¥872M |
| Net income | CN¥652M | CN¥735M | CN¥707M | CN¥847M | CN¥703M |
| Free cash flow | CN¥551M | CN¥760M | CN¥607M | CN¥790M | CN¥251M |
| Capital expenditure | CN¥152M | CN¥127M | CN¥117M | CN¥195M | CN¥474M |
| Total debt | CN¥94.6M | CN¥76.1M | CN¥152M | CN¥262M | CN¥208M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Anhui Anke Biotechnology (Group) 300009.SZ | $1.88B | -12% | -9% | 30% | 18.1× | 8.0% |
| Changchun High-Tech Industry (Group) 000661.SZ | $4.52B | -13% | -18% | -1% | 30.3× | 32.4% |
| Novo Nordisk A/S NOVO-B.CO | $177B | -6% | +6% | 48% | 11.8× | -0.5% |
| Pfizer PFE | $160B | +9% | +1% | 26% | 9.9× | -4.3% |
| Merck KGaA MRK.DE | $71.3B | +16% | +1% | 19% | 17.4× | 7.4% |
| Ascendis Pharma A/S ASND | $16.9B | +12% | +94% | 18% | 28.0× | 19.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300009.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.8% | +1.7% | 6th lowest of 21 |
| 6-month return | -12.5% | -7.3% | 9th lowest of 21 |
| Distance from 52-week high | -34.4% | -27.6% | 7th lowest of 21 |
| Revenue growth (TTM) | -9.4% | +11.8% | lowest of 20 |
| Operating margin | 30.0% | 13.3% | 4th highest of 20 |
| Forward P/E | 18.1× | 18.4× | 10th cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | 8.0% | 0.3% | 5th most demanding of 13 |
| Growth delivered (Del g) | +9.3% | +6.8% | 5th highest of 13 |
| Hurdle (Req g minus delivered) | -1.3 pp | -12.1 pp | 6th most demanding of 13 |
| ROIC minus cost of capital | +10.0 pp | +0.1 pp | 6th highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Anhui Anke Biotechnology (Group) 300009.SZ | China | $1.88B | -12% | -9% | 30% | 18.1× | 8.0% | +9.3% |
| Pfizer PFIZER.NS | India | $1.88B | -20% | +12% | 34% | 21.9× | 11.2% | +2.4% |
| Tibet Rhodiola Pharmaceutical 600211.SS | China | $1.87B | -8% | +13% | 27% | 12.5× | -1.2% | +16.7% |
| Cohance Lifesciences COHANCE.NS | India | $1.87B | +7% | +14% | 2% | 96.3× | n/a | n/a |
| Alivus Life Sciences ALIVUS.NS | India | $1.90B | +36% | +8% | 31% | 23.8× | 20.1% | +6.2% |
| CSPC Hunan Jingfeng Pharmaceutical 000908.SZ | China | $1.85B | -38% | +5% | -18% | n/a | n/a | n/a |
| Dermapharm DMP.DE | Germany | $1.85B | -29% | +2% | 21% | 13.2× | -3.4% | +8.0% |
| Shilpa Medicare SHILPAMED.NS | India | $1.91B | +94% | +37% | 21% | 54.3× | n/a | n/a |
| Grand Pharmaceutical 0512.HK | Hong Kong | $1.93B | -25% | +7% | 13% | 9.4× | 1.2% | +14.1% |
| Shenyang Xingqi Pharmaceutical 300573.SZ | China | $1.83B | -25% | +17% | 33% | 13.0× | 5.4% | +29.1% |
| Tsumura & 4540.T | Japan | $1.93B | +6% | +13% | 18% | 10.4× | n/a | n/a |
| Jinyu Bio-Technology 600201.SS | China | $1.93B | -21% | +22% | 10% | 59.0× | 23.4% | -2.5% |
| Guobang Pharma 605507.SS | China | $1.82B | -6% | +3% | 12% | 15.7× | -6.0% | +7.4% |
| Harmony Biosciences HRMY | United States | $1.94B | +6% | +20% | 22% | 8.6× | -10.5% | +40.3% |
| China National Accord Medicines 000028.SZ | China | $1.81B | -3% | 0% | 2% | 10.8× | -9.5% | +4.2% |
| OneSource Specialty Pharma ONESOURCE.NS | India | $1.95B | -14% | +11% | 6% | 44.6× | n/a | n/a |
| Biohaven BHVN | United States | $1.95B | +46% | n/a | n/a | n/a | n/a | n/a |
| Zymeworks ZYME | United States | $1.81B | +5% | +98% | 17% | 160.4× | n/a | n/a |
| Ultragenyx Pharmaceutical RARE | United States | $1.81B | -24% | +16% | -64% | 9.6× | n/a | n/a |
| Qingdao Baheal Medical 301015.SZ | China | $1.81B | +2% | -6% | 8% | 21.0× | 10.1% | +5.0% |
| Shenzhen Hepalink Pharmaceutical 002399.SZ | China | $1.80B | -12% | -6% | 8% | 25.8× | -0.7% | +0.5% |